Get the Stockscreener App
109.50
3.95%
-4.50
After Hours:
109.80
0.30
+0.27%
Axsome Therapeutics Inc stock is traded at $109.50, with a volume of 700.86K.
It is down -3.95% in the last 24 hours and up +28.63% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$114.00
Open:
$113.67
24h Volume:
700.86K
Relative Volume:
0.96
Market Cap:
$5.20B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-16.77
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+0.60%
1M Performance:
+28.63%
6M Performance:
+28.04%
1Y Performance:
+15.49%
1-Day Range:
$109.35
$114.06
1-Week Range:
$103.98
$114.06
52-Week Range:
$64.11
$114.06
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
109.50 | 5.20B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 at Truist Financial - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Mizuho lifts Axsome stock target to $137, maintains Outperform - MSN
Calamos Advisors LLC Invests $1.08 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Short Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Declines By 13.1% - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week HighShould You Buy? - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
FY2024 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
RBC Capital lifts Axsome stock target to $143, sees launch potential - MSN
Axsome Therapeutics' SWOT analysis: CNS drug developer's stock poised for growth - MSN
(AXSM) Proactive Strategies - Stock Traders Daily
H.C. Wainwright lifts Axsome stock target to $190 on FDA nod - MSN
Axsome Therapeutics: Strategic Launch and Study Upside Drive Buy Rating - TipRanks
Truist Securities Adjusts Axsome Therapeutics Price Target to $190 From $180, Maintains Buy Rating - Marketscreener.com
Mizuho Raises Price Target on Axsome Therapeutics to $137 From $122, Keeps Outperform Rating - Marketscreener.com
RBC Lifts Price Target on Axsome Therapeutics to $143 From $139, Keeps Outperform Rating - Marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year HighHere's What Happened - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at Royal Bank of Canada - MarketBeat
Moody Aldrich Partners LLC Sells 15,506 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - MSN
Axsome gets FDA approval for Symbravo for migraine - MSN
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises - MSN
Musculoskeletal Pain Pipeline 2024: Therapies, MOA Insights, - openPR
FDA approves Axsome's novel migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
Axsome’s Migraine Medicine Clears FDA Bar - BioSpace
Redemption complete for Axsome’s Symbravo in migraine - The Pharma Letter
Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs - MSN
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewswire
FDA Victory: Axsome's Revolutionary Migraine Drug SYMBRAVO Gets Green LightTop Expert Reveals Clinical Impact - StockTitan
FDA approves new migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
FDA approves new migraine treatment SYMBRAVO - MSN
Axsome Shares Up Post Market After Hitting Record High on FDA Approval - MarketWatch
US FDA approves Axsome Therapeutics' migraine drug - Reuters
Big Moves in Tech: Buying Apple, Selling Dell - The Globe and Mail
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - The Manila Times
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® - GlobeNewswire
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the - The Bakersfield Californian
TD Cowen lifts Axsome stock target to $155, maintains Buy rating - MSN
Excessive Daytime Sleepiness Pipeline 2024: Key Companies, - openPR
Is Trump Media & Technology Group Stock a Buy? - The Globe and Mail
Axsome Therapeutics stock hits 52-week high at $105.18 By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):